791873.fig.004a
(a) First 24 h
791873.fig.004b
(b) RM
791873.fig.004c
(c) IM
791873.fig.004d
(d) PM
Figure 4: Median 12 h pH level in different intravenous infusion regimens (placebo, famotidine 20 mg, omeprazole 20 mg, famotidine 10 mg plus omeprazole 10 mg (half-concomitant), famotidine 20 mg plus omeprazole 20 mg (full-concomitant)) in CYP2C19 RM, IM, and PM genotype groups (a). Median 6-h pH-time profiles of intravenous infusions of famotidine alone, omeprazole alone, and a concomitant of famotidine and omeprazole in the RM (b), IM (c), and PM genotype groups (d). * using the Wilcoxon’s signed rank test, when significant differences were obtained by the Friedmann’s test.